A dose-escalation study of HP501, a highly selective URAT1 inhibitor, in male Chinese patients with hyperuricemia.
Ding R, Deng X, Chen L, Zhen Y, Li X, Xiong T, Zhang Y, Chen H, Hu X, Li Y, Zhou Y, Jiang F, Peng Q, Wang X.
Ding R, et al. Among authors: zhang y.
Sci Rep. 2023 Dec 14;13(1):22190. doi: 10.1038/s41598-023-49052-x.
Sci Rep. 2023.
PMID: 38092845
Free PMC article.
Clinical Trial.